How does a license work?
A lifetime license, sometimes referred to as a perpetual or outright license, offers you the opportunity to acquire an ON1 application permanently with just a single payment. This means you own the software outright, and it includes minor software updates. Additionally, you'll benefit from discounted upgrade pricing and substantial savings when transitioning to future major upgrade versions. For example, if you own version 2023, you'll enjoy savings when upgrading to future major versions, such as version 2024.
What is a Perpetual License?
A perpetual license is a one-time payment option that grants you permanent ownership of the software. With this license, you don't have to worry about recurring subscription fees or annual renewals. You make a single payment, and the software is yours to use indefinitely.
What's Included?
When you purchase an outright license, you not only gain access to the current version but also receive some additional benefits:
-
Minor Software Updates: Your lifetime license includes access to minor software updates. This means you'll continue to receive bug fixes, performance enhancements, and new features within the same major version of ON1 that you initially purchased.
-
Discounted Upgrade Pricing: In addition to minor updates, ON1 provides lifetime license holders with discounted pricing on major version upgrades. For example, if you own version 2023, you'll save when upgrading to future versions, such as version 2024.
The Advantages of a Lifetime License
Choosing an outright license comes with several advantages:
-
Cost-Efficiency: With a one-time payment, you avoid recurring subscription costs, making it a cost-effective choice for long-term use.
-
Permanent Ownership: You own the software outright, ensuring you can continue to use it even if you choose not to upgrade in the future.
-
Savings on Upgrades: Discounted upgrade pricing saves you money when you decide to move to the latest major version, making it an attractive option for staying up to date.
Comments
0 comments
Article is closed for comments.